Introduction
Cardiovascular disease is the leading cause of death in the United States and world-wide (Go et al., 2013) . Coronary artery disease is associated with several pre-disposing risk factors, including low levels of high-density lipoprotein (HDL) and its primary anti-atherogenic protein component, apolipoprotein A-I (apo A-I) (Emerging Risk Factors Collaboration et al., 2012) . However, clinical trials targeting HDL with therapeutic agents that increase HDL through reducing the turnover of HDL have not shown benefit (AIM- HIGH Investigators et al., 2011; Barter et al., 2007; HPS2-THRIVE Collaborative Group et al., 2014; Schwartz et al., 2012; Singh et al., 2007) . It has been suggested that increasing HDL levels through de novo synthesis of apo A-I may yield functional HDL molecules that are more capable in enhancing reverse cholesterol transport and can reduce the risk of atherogenesis (Feig et al., 2014; Mooradian and Haas, 2015) . However, there is a paucity of therapeutic agents that increase de novo synthesis of apo A-I and HDL.
We recently identified several drugs that increase hepatic apo A-I production using a high-throughput screening approach with a library of > 700 compounds that are FDA approved or in phase 2 or phase 3 clinical trials. One of the compounds, the H 1 antihistamine azelastine, increased hepatic apo A-I production over 50% (Plazarte et al., 2017) . This novel observation suggests that antihistamines may increase apo A-I gene expression.
Histamine H 1 receptor is a G-protein-coupled receptor that is expressed in mast cells and in hepatocytes, including HepG2 cells (Falus et al., 1989; Meretey et al., 1991) . In the absence of histamine, the histamine H 1 receptor is constitutively active, however its level of activity is enhanced by histamine (which stabilizes the receptor in an active state) and repressed by antihistamines (that stabilize the receptor in an inactive state) (Monczor et al., 2013) . Though histamines have been shown to be associated with the growth and progression of atherosclerotic lesions in the coronary artery (Atkinson et al., 1994; Kovanen et al., 1995) , there are few studies examining the effects of antihistamines on lipids. Liao et al. (1997) showed that the H 1 antihistamine fexofenadine increased HDL levels in rats while histamine reduced plasma HDL levels and suppressed hepatic low-density lipoprotein (LDL) receptor expression. Furthermore, histamine H 1 receptors and antihistamines were also shown to suppress atherosclerosis in apo E -/-mice fed a high-fat diet for three months (Yamada et al., 2015) .
Activation of the histamine H 1 receptor induces several intracellular signaling pathways by increasing diacylglycerol (DAG) levels, inositol-1,4,5-triphosphate production, phospholipase C and phospholipase A 2 activity, and increasing intracellular calcium levels (Hill et al., 1997) . These pathways activate the transcription factor nuclear factor-κB (NF-κB), inducing the expression of pro-inflammatory mediators (Bakker et al., 2001) . H 1 antihistamines decrease DAG and calcium levels and prevent the induction of NF-κB. Importantly, NF-κB also represses apo A-I gene expression in response to lipopolysaccharide by inhibiting peroxisome proliferator-activated receptor α (Morishima et al., 2003) . The fibrate-responsive transcription factor peroxisome proliferator activated receptor α is a key regulator of apo A-I gene expression and hepatic HDL synthesis, though induction of apo A-I gene expression by gemfibrozil or fenofibrate is only modest (Vu-Dac et al., 1994 , 1998 . These observations taken together suggest that histamine regulates apo A-I gene expression.
Materials and methods

Materials
Azelastine, histamine, Dulbecco's modified essential medium (DMEM), fetal bovine serum (FBS), newborn calf serum, and penicillin/ streptomycin were obtained from Thermo-Fisher Scientific (Pittsburg, PA).
14 C-Chloramphenicol was purchased from Perkin-Elmer (Waltham, MA). The enzyme immunoassay (EIA) kit for measuring human apo A-I was purchased from Mab-Tech (Cincinnati, OH). Lipofectamine was purchased from Invitrogen (Carlsbad, CA). Avian Myeloblastosis virus (AMV) reverse transcriptase and SYBER green reagents for polymerase chain reaction (PCR) were purchased from Promega (Madison, WI) and Bio-Rad (Hercules, CA), respectively. The H 1 histamine receptor antagonists fexofenadine, cetirizine, diphenhydramine, and loratidine, and the H 2 histamine receptor antagonists ranitidine, cimetidine, and famotidine were purchased from Alfa Aesar (Ward Hill, MA). All other chemicals and reagents were purchased from either Thermo-Fisher Scientific or Sigma-Aldrich.
Cell culture
HepG2 hepatocytes were purchased from American Type Culture Collection (Manassas, VA) and maintained in DMEM containing 10% FBS, 10 μg/ml streptomycin, and 10 units/ml penicillin. Primary human hepatocytes were purchased from Lonza Walkersville Inc. (Walkersville, MD) and maintained in Hepatocyte Plating medium (Corning) supplemented as described by the supplier. All cells were grown in a humidified incubator at 37°C and 5% CO 2 .
Transient transfection and chloramphenicol acetyltransferase (CAT) assay
To examine the effect of H 1 and H 2 receptor agonists and antagonists on apo A-I promoter activity, HepG2 cells were transfected with a series of reporter plasmids containing various portions of the apo A-I gene promoter driving expression of the CAT reporter gene. Specifically, plasmids containing 474, 425, 375, 325, 186, 170, 144 , and 46 bp of the 5′-flanking region of the apo A-I gene promoter were employed to identify a potential azelastine/histamine response element (Haas et al., 2003) . Other plasmids containing site A (pA1.A.CAT) or lacking site A (pA1.ΔA.CAT) adjacent to the SV40 virus early region promoter driving CAT expression were used as described previously (Haas et al., 2003) . Briefly, HepG2 in 6-well plates were transfected with 1 μg of the CAT reporter plasmid as well as the plasmid pCMV.SPORT.β-gal, to control for transfection efficiency using Lipofectamine. After 24 or 48 h, the cells were collected and assayed for CAT (Gorman et al., 1982) and β-galactosidase (Herbomel et al., 1984) activity.
Measurement of cell viability
Cell toxicity was measured by the loss of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction (van de Loosdrecht et al., 1994) . HepG2 cells were treated as described in each figure. After collection of the conditioned medium, MTT dissolved in phosphate buffered saline (PBS) (5 mg/ml) was added to each well at a concentration of 0.5 μg/ml and incubated for 2 h at 37°C. The media was removed and the formazan crystals were dissolved in 500 μl of 0.1 M HCl and 10% Triton X-100 in isopropanol. After 15 min, MTT activity was measured at 570 nm with background correction of 690 nm with a BioTek ELx800 microplate spectrophotometer (Winooski, VT).
Measurement of apo A-I protein and mRNA levels
Apo A-I protein levels and mRNA were measured by EIA and quantitative real-time reverse transcription PCR (RT-PCR), respectively. Apo A-I protein levels were measured in the conditioned media from cells treated with histamine and azelastine with an EIA kit and normalized to protein content which was measured using the bicinchoninic acid (BCA) assay (Smith et al., 1985) . Briefly, media samples (100 μl) were incubated in 96-well plates coated with an apo A-I antibody, followed by an incubation with a second anti-apo A-I biotinylated antibody. After 24 h, the streptavidin-horseradish peroxidase conjugate was added and binding detected by addition of tetramethylbenzidine (TMB). After addition of 2 N H 2 SO 4 , apo A-I content was measured with the BioTek ELx800 microplate spectrophotometer and changes in apo A-I protein levels calculated using Excel.
Apo A-I mRNA levels were measured by quantitative RT-PCR. Briefly, total RNA will be isolated from cells treated as described (Chomczynski and Sacchi, 1987) . Three μg of RNA was reverse transcribed using AMV reverse transcriptase and the cDNA was used for PCR amplification of apo A-I and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA with primers specific for each gene (Haas et al., 2011) with the MyiQ Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA). Apo A-I mRNA levels were then normalized to GAPDH expression using the Δ Δct method.
Statistical analysis
All results are expressed as mean ± S.D. Analysis of variance (ANOVA) followed by the Neuman-Keuls procedure for subgroup analysis was carried out using Statistica. Significance was defined as a two-tailed P < .05.
Results
The effect of histamine and azelastine on apo A-I gene expression
Treatment with 100 nM histamine for 24 h had no effect on apo A-I levels. To determine if longer exposure to histamine is required to observe potential effects on apo A-I gene expression, HepG2 cells were treated with 100 nM histamine for 0, 1, 3, 6, 24, 48, 72, and 96 h and apo A-I levels were measured in the conditioned medium by EIA (Fig. 1A ) and cell toxicity was measured using the MTT assay (Fig. 1B) . Treatment with 100 nM histamine suppressed apo A-I levels significantly relative to control cells at 48 h. Furthermore, histamine treatment was not toxic at this dose for up to 96 h.
HepG2 cells were then treated with 0, 1, 10, 100 nM azelastine and 1, 10, and 100 μM azelastine for 24 h and apo A-I levels were measured in the conditioned medium by EIA ( Fig. 2A) and cell toxicity was measured using the MTT assay (Fig. 2B ). Azelastine concentrations greater than 100 nM induced apo A-I levels significantly, however at 100 μM, significant drug-induced toxicity was observed and apo A-I levels were reduced. To determine the kinetics of induction, HepG2 cells were treated with 100 nM azelastine for 0, 1, 3, 6, 24, 48, 72, and 96 h and apo A-I levels were measured in the conditioned medium (Fig. 3A) and cell toxicity was measured using the MTT assay (Fig. 3B) . The results showed that apo A-I induction by azelastine required 24 h and that this concentration of azelastine was safe for up to 96 h of treatment.
The effect of histamine and azelastine on apo A-I mRNA levels and gene promoter activity
To demonstrate if histamine and azelastine regulate apo A-I protein levels by either repressing or inducing apo A-I mRNA levels, respectively, HepG2 cells were treated with 0, 1, 10, and 100 nM and 1, 10, and 100 μM of histamine for 48 h (Fig. 4A ) or similar concentrations of azelastine for 24 h (Fig. 4B ) and apo A-I and GAPDH mRNA levels were measured by real-time RT-PCR. Apo A-I mRNA levels were normalized to GAPDH levels. Histamine decreased apo A-I mRNA levels at concentrations greater than 100 nM while azelastine increased apo A-I mRNA levels at doses greater than 100 nM. These results suggest that changes in apo A-I protein levels observed with histamine or azelastine treatment are due to changes in its mRNA.
Since histamine suppressed and azelastine induced apo A-I mRNA levels, changes in apo A-I promoter activity were measured by transient transfection of HepG2 cells with the reporter plasmid pAI.474. CAT and treated with different concentrations of histamine for 48 h (Fig. 5A ) or similar amounts of azelastine for 24 h (Fig. 5B ). At concentrations greater than 100 nM, histamine suppressed apo A-I promoter activity. In contrast, treatment with 100 nM azelastine induced apo A-I promoter activity, however treatment with 100 μM azelastine resulted in less promoter activity, most likely due to toxicity. These results, as well as those described above indicate that histamine suppresses apo A-I gene expression by decreasing transcription of the apo A-I gene promoter. Likewise, azelastine induces apo A-I gene expression by enhancing apo A-I gene promoter activity.
Identification of a histamine-responsive element in the apo A-I gene promoter
Since histamine suppressed apo A-I gene promoter activity, we sought to identify and characterize potential histamine-responsive element in the apo A-I gene promoter. HepG2 cells were transfected with a series of apo A-I reporter plasmids containing deletions within the apo A-I gene promoter and treated with either 100 nM histamine for 48 h (Fig. 6A) or 100 nM azelastine for 24 h (Fig. 6B) and CAT activity was measured. Histamine treatment decreased CAT activity in cells transfected with 474, 425, 375, and 325 bp of the apo A-I gene promoter, however histamine treatment had no effect in cells transfected with 186, 170, 144, and 46 bp of the apo A-I gene promoter. In contrast, azelastine treatment induced apo A-I promoter activity in cells transfected with 474, 425, 375, and 325 bp of the apo A-I gene promoter, whereas azelastine treatment had no effect on CAT activity in cells transfected with 186, 170, 144, and 46 bp of the apo A-I gene promoter. These results suggest that histamine and azelastine regulate apo A-I promoter activity through a similar transcriptional mechanism.
The apo A-I gene promoter contains a peroxisome proliferator activated receptor α/retinoid-X-receptor binding site, site A, between −325 and −186 (Haas et al., 2003) . To determine if site A mediates the effects of histamine and azelastine on apo A-I promoter activity. HepG2 cells were transfected with the plasmids pA1.A.CAT (containing Fig. 1 . The effect of histamine on apo A-I secretion and toxicity in HepG2 cells. HepG2 cells were treated with 100 nM histamine for 0, 1, 3, 6, 24, 48, 72, and 96 h and apo A-I levels were measured in the conditioned medium by EIA (A) and cytotoxicity was assessed using the MTT assay (B). Histamine treatment inhibited apo A-I secretion significantly at 48 h and had no effect on cell viability throughout the 96 h course of the experiment. N = 6; *, P < .05 relative to control cells treated with DMSO. Fig. 2 . The effect of azelastine on apo A-I secretion and toxicity HepG2 cells. HepG2 cells were treated with 0, 1, 10, and 100 nM and 1, 10, and 100 μM azelastine for 24 h and apo A-I levels were measured in the conditioned medium by EIA (A) and cytotoxicity was assessed using the MTT assay (B). Azelastine was effective at inducing apo A-I levels at concentrations greater than 100 nM. The observed decrease in apo A-I levels at 100 μM azelastine was due to its toxicity at this concentration. N = 6; *, P < .05 relative to cells treated with an equivalent amount of the solvent DMSO.
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European Journal of Pharmacology 823 (2018) [49] [50] [51] [52] [53] [54] [55] [56] [57] two copies of site A in front of the SV40 viral gene promoter) or pA1.ΔA.CAT (no site A) and treated with 100 nM histamine for 48 h or 100 nM azelastine for 24 h. Treatment with histamine suppressed apo A-I promoter activity only in cells transfected with the site A-containing plasmid (Fig. 7) . Likewise, treatment with azelastine increased CAT activity in cells transfected with the site A-containing plasmid. These results, as well as those described above suggest that azelastine and histamine regulate apo A-I gene expression through site A.
The effect of select H 1 histamine receptor and H 2 histamine receptor antagonists on hepatic apo A-I secretion
HepG2 cells were treated with 0, 1, 10, and 100 nM and 1, 10, 50, and 100 μM concentrations of H 1 histamine receptor antagonists fexofenadine (Fex), cetirizine (Cet), diphenhydramine (Dip), and loratidine (Lor), and the H 2 histamine receptor antagonists ranitidine (Ran), cimetidine (Cim), and famotidine (Fam) for 24 h and apo A-I levels were measured in the conditioned medium and normalized to protein content. With the exception of loratidine which exhibited toxicity at several of the higher concentrations examined (Fig. 8, panel  H) , treatment with cetirizine, fexofenadine, and diphenhydramine all increased apo A-I secretion significantly, though the former two were slightly more effective and were active at lower levels (Fig. 8, panels A,  C , E, and G). In contrast, treatment with the H 2 histamine receptor antagonists ranitidine, cimetidine, and famotidine had no observable toxicity but had no effect on apo A-I levels (Fig. 9 , panels A, C, and E).
Since loratidine exhibited substantial toxicity to HepG2 cells, we treated primary human hepatocytes with different concentrations of loratidine for 24 h and cell toxicity was measured using the MTT assay and apo A-I levels in the conditioned medium was measured by EIA.
Treatment of primary human hepatocytes with loratidine increased apo A-I secretion into the conditioned medium (Fig. 10, panel A) and had no effect on cell viability (Fig. 10, panel B) . These results as well as those described above, suggest that H 1 histamine receptor antagonists are effective at inducing apo A-I gene expression in hepatocytes. In contrast, H 2 histamine receptor antagonists had no effect.
Discussion
Several recent studies suggest that functional HDL may be critical to its beneficial atheroprotective effects. There is considerable debate regarding which functions of HDL are critical for its cardioprotective properties in vivo. Plasma HDL may be more atheroprotective if apo A-I levels are increased by enhanced de-novo synthesis rather than by interfering with its turnover. Alternatively, several studies using reconstituted wild type apo A-I (Shaw et al., 2008) or apo A-I Milano (Arg173 → Cys173) (Nissen et al., 2003) infusion demonstrated rapid regression of atherosclerotic lesion size as determined by intravascular ultrasound. Pre-clinical studies in mice using adeno-associated viral vectors to increase apo A-1 and apo A-I Milano production in mice (Lebherz et al., 2007) as well as apo A-I mimetic peptides have been shown to reverse atherosclerosis (Navab et al., 2010) . Thus there is substantial interest in identifying novel pathways that impact de novo synthesis of apo A-I. Most clinically used pharmaceuticals as well as those under recent development including niacin and cholesterol ester transfer protein inhibitors, elevate HDL levels by prolonging its half-life in the plasma. Though fibrates (Vu-Dac et al., 1994, 1998), statins (Martin et al., 2001) , and pioglitazone (Sakamoto et al., 2000) have been shown to Fig. 3 . Kinetics of the effects of azelastine on apo A-I secretion. HepG2 cells were treated with 100 nM azelastine for 0, 1, 3, 6, 24, 48, 72, and 96 h and apo A-I levels were measured in the conditioned medium by EIA (A) and cells cell toxicity was measured with the MTT assay (B). There was no change in apo A-I levels at 6 h, however at 24 h, near maximal induction was apparent. There was also no toxicity apparent at any of the time points. N = 6; *, P < .05 relative to control cells treated with the solvent DMSO. Fig. 4 . The effect of histamine and azelastine on apo A-I mRNA levels. HepG2 cells were treated with 0, 1, 10, 100 nM and 1, 10, and 100 μM histamine for 48 h and similar concentrations of azelastine for 24 h and apo A-I and GAPDH mRNA levels were measured by quantitative real-time PCR; Apo A-I mRNA levels were then normalized to GAPDH expression. Treatment with 100 nM histamine (A) suppressed apo A-I mRNA levels, while treatment with 100 nM azelastine increased apo A-I mRNA expression (B). N = 3; *, P < .05 relative to control cells treated with the solvent DMSO.
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European Journal of Pharmacology 823 (2018) [49] [50] [51] [52] [53] [54] [55] [56] [57] induce apo A-I gene expression at the level of transcription, their effects are modest. The bromodomain and extra-terminal (BET) inhibitor RVX-208 was shown to induce apo A-I gene expression at the transcriptional level (Ghosh et al., 2017) and is in clinical trials (Di Bartolo et al., 2016) . This first-of-class epigenetic regulator of gene expression has also been shown to alter the HDL lipidome in a favorable way by increasing its sphingolipid and phospholipid content (Siebel et al., 2016) and to reduce the levels of several complement cascade components (Wasiak et al., 2017) . Antihistamines may also have dual effects on atherosclerosis by inhibiting dyslipidemia and inflammation. Previous studies in our laboratory indicated that several compounds with antihistamine activity induce hepatic apo A-I gene expression, including the second generation topical antihistamine azelastine (Plazarte et al., 2017) . This novel observation prompted us to examine whether or not histamine regulates apo A-I gene expression. In this study, we also demonstrated that azelastine as well as several other H 1 histamine receptor antagonists induce apo A-I gene expression. Treatment with histamine suppressed apo A-I secretion at 48 h, as well as apo A-I mRNA levels (Fig. 4) and apo AI gene promoter activity (Fig. 5) . In contrast, treatment with azelastine concentrations greater than 100 nM for 24 h increased apo A-I secretion (Figs. 2 and 3) , apo A-I mRNA (Fig. 4) , and apo A-I gene promoter activity (Fig. 5) . Further studies demonstrated that the peroxisome proliferator activated receptor α element in the apo A-I gene promoter was essential in mediating the effects of both azelastine and histamine (Fig. 7) . Finally, other select H1 histamine receptor antagonist including cetirizine, fexofenadine, and Fig. 5 . The effect of histamine and azelastine on apo A-I gene promoter activity. HepG2 cells were transfected with the plasmid pAI.474.CAT and the plasmid pCMV.SPORT.β-gal (to control for transfection efficiency) and treated with 0, 1, 10, and 100 nM and 1, 10, and 100 μM histamine for 48 h (A) or similar concentrations of azelastine for 24 h. Treatment with 100 nM and higher concentrations of histamine suppressed apo A-I promoter activity. In contrast, treatment with 100 nM and higher concentrations of azelastine increased apo A-I gene promoter activity, with exception of the 100 μM dose which was most likely toxic. N = 3; *, P < .05 relative to cells exposed to DMSO. , and 325 bp of the apo A-I gene promoter but had no effect on promoter activity in cells transfected with the plasmid containing 186 bp of the apo A-I gene promoter. Azelastine induced apo A-I promoter activity when cells were transfected with plasmids containing 474, 425, 375, and 325 bp of the apo A-I gene promoter but had no effect in cells transfected with 186 bp or less. These results suggest that both azelastine and histamine regulate apo A-I gene expression through similar cis-sequences. N = 3; *, P < .05 relative to cells treated with the solvent DMSO. Fig. 7 . Histamine and azelastine regulate apo A-I expression through site A. HepG2 cells were transfected with the plasmids pA1A.CAT or pA1ΔA.CAT and the plasmid pCMV.SPORT.β-gal (to assess transfection efficiency) and treated with or without 100 nM histamine or with or without 100 nM azelastine for 48 h and reporter gene expression was measured. In cells transfected with the plasmid containing site A (pA1A.CAT), treatment with histamine and azelastine inhibited and inhibited reporter gene expression, respectively. In cells transfected with the plasmid lacking site A (pA1ΔA.CAT), histamine and azelastine had no effect. N = 3; *, P < .05 relative to cells treated with DMSO.
M.J. Haas et al. European Journal of Pharmacology 823 (2018) 49-57 Fig. 8. The effect of select H 1 histamine receptor antagonists on apo A-I secretion from HepG2 cells. HepG2 cells were treated with 0, 1, 10, and 100 nM and 1, 10, 50 and 100 μM cetirizine (A), fexofenadine (C), diphenhydramine (E), and loratidine (G) for 24 h and apo A-I levels in the conditioned medium were measured by EIA and normalized to protein content. Cytotoxicity (panels B, D, F, and H) was assessed with the MTT assay. Treatment with cetirizine, fexofenadine, and diphenhydramine increased apo A-I secretion and possessed no toxicity at any of the concentrations tested. In contrast, treatment with loratidine (G) decreased apo A-I secretion. However, this decrease in apo A-I levels is most likely due to toxicity since loratidine also significantly decreased cell viability. N = 6; *, P < .05 relative to cells treated with the solvent DMSO.
M.J. Haas et al. European Journal of Pharmacology 823 (2018) [49] [50] [51] [52] [53] [54] [55] [56] [57] diphenhydramine (a first generation antihistamine) also induced apo A-I secretion in HepG2 cells (Fig. 8) . Interestingly, in HepG2 cells, loratidine was toxic at several of the higher concentrations tested but did not induce apo A-I secretion at the lower concentrations. In contrast, loratidine was not toxic to primary human hepatocytes and clearly induced apo A-I levels in the conditioned medium (Fig. 10) . Whether or not this is due to a potential anti-tumor effect in HepG2 cells is under investigation. Treatment with the H 2 histamine receptor antagonists cimetidine, famotidine, and ranitidine had no effect on apo A-I expression but exhibited no cytotoxicity (Fig. 9 ). These observations indicate that select H 1 histamine receptor antagonists may elevate HDL levels by inducing de novo apo A-I levels. There are several limitations to our study. First, we used HepG2 cells for our analyses. Though these cells possess some characteristics of differentiated hepatocytes relative to Hep3B cells as assessed by proteome profiling (Slany et al., 2010) , they are tumor cells and are adapted to culture. We routinely use cells less than 30 passages in our experiments. It is not clear if we would obtain similar results with primary human hepatocytes. There is also concern with the results we obtained with loratidine. HepG2 cells treated with this potent H 1 histamine receptor antagonist exhibited much more toxicity than cells treated with azelastine which also demonstrated toxicity at the highest concentration used. Relative to the other H 1 histamine receptor antagonists tested, loratidine is the most potent. It is also important to point out that H 1 -antihistamines have been shown to promote hepatic steatosis in C57Bl/6 mice fed a high-fat diet (Raveendran et al., 2014) . This was not observed in apolipoprotein E knockout mice indicating that lack of apo E is protective (Raveendran et al., 2014) . It remains to be determined what effect antihistamines have on plasma apo A-I and HDL levels in humans.
It is noteworthy that the kinetics of the effects of histamine and azelastine were different. Induction of apo A-I gene expression by azelastine required only 24 h while inhibition of apo A-I gene expression by histamine required at least 48 h. It is possible that inhibition of Fig. 9 . The effect of select H 2 histamine receptor antagonists on apo A-I secretion from HepG2 cells. HepG2 cells were treated with 0, 1, 10, and 100 nM and 1, 10, 50, and 100 μM cimetidine (A), famotidine (C), and ranitidine (E) for 24 h and apo A-I levels were measured in the conditioned medium by EIA and normalized to protein content. Cytotoxicity (panels B, D, and F) was measured with the MTT assay. Treatment with all three H 2 histamine receptor antagonists had no effect on apo A-I secretion and had no effect on HepG2 cell viability. N = 6. M.J. Haas et al. European Journal of Pharmacology 823 (2018) [49] [50] [51] [52] [53] [54] [55] [56] [57] apo A-I gene expression by histamine requires induction or repression of another factor that regulates the apo A-I gene promoter. We identified the peroxisome proliferator activated receptor α element in the apo A-I gene promoter as mediating the effects of azelastine and histamine on apo A-I gene expression. This element has been shown to bind peroxisome proliferator activated receptor α/retinoid-X-receptor α (RXRα) heterodimers (Vu-Dac et al., 1994 , 1998 as well as NF-κB (Morishima et al., 2003) . The latter transcription factor was shown to suppress peroxisome proliferator activated receptor α function on the apo A-I gene expression in hepatocytes treated with lipopolysaccharide.
Conclusions
Our results strongly suggest that histamine regulates hepatic apo A-I gene expression. Likewise, several H 1 receptor antagonists were shown to induce apo A-I gene expression. These findings suggest that antihistamines may have utility in treating hypoalphalipoproteinemia.
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